KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Long-Term Investments: 2019-2024

Historic Long-Term Investments for Royalty Pharma (RPRX) over the last 6 years, with Dec 2024 value amounting to $693.5 million.

  • Royalty Pharma's Long-Term Investments fell 53.98% to $302.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $302.5 million, marking a year-over-year decrease of 53.98%. This contributed to the annual value of $693.5 million for FY2024, which is 58.66% up from last year.
  • Royalty Pharma's Long-Term Investments amounted to $693.5 million in FY2024, which was up 58.66% from $437.1 million recorded in FY2023.
  • Royalty Pharma's 5-year Long-Term Investments high stood at $693.5 million for FY2024, and its period low was $397.2 million during FY2022.
  • Over the past 3 years, Royalty Pharma's median Long-Term Investments value was $437.1 million (recorded in 2023), while the average stood at $509.3 million.
  • Its Long-Term Investments has fluctuated over the past 5 years, first fell by 8.78% in 2022, then soared by 58.66% in 2024.
  • Royalty Pharma's Long-Term Investments (Yearly) stood at $454.9 million in 2020, then fell by 4.30% to $435.4 million in 2021, then decreased by 8.78% to $397.2 million in 2022, then grew by 10.05% to $437.1 million in 2023, then surged by 58.66% to $693.5 million in 2024.